F. Saini; Dr. V. R. Kandula; G. VenugopalEngender Health Society (Improving Women's Health Worldwide); CII Confederation of Indian Industry; Population Foundation of India; et al.
(2006)
C2
The new WHO recommendations for the treatment of isoniazid-resistant, rifampicin-susceptible TB are based upon a review of evidence from patients treated with such regimens by a Guideline Development Group in conformity with WHO requirements for evidence-based policies.
Plus de 2000 enfants meurent chaque jour des suites de traumatismes involontaires ou accidentels. Chaque année des dizaines de milliers d'autres sont hospitalisés pour des blessures qui les laissent souvent handicapés à vie.
Ce rapport conjoint de l'OMS et de l'UNICEF établit le premier b...ilan mondial des principales causes à l'origine des traumatismes involontaires touchant des enfants: les accidents de la route, les noyades, les brûlures, les chutes et les empoisonnements.more
The WHO operational handbook on tuberculosis: tuberculosis preventive treatment is the companion, implementation guide to the 2020 WHO guidelines on TB preventive treatment.[1] Just as these guidelines are the first to be released under the rubric of the WHO consolidated TB guidelines, this handbook... will be the first in a modular series of practical guides meant for the implementers of various aspects of the programmatic management TB.more
La publicación describe los procedimientos estandarizados para la atención integral de las personas diagnosticadas con tuberculosis y Virus de Inmunodeficiencia Humana en los servicios de salud a nivel nacional, así como los procesos de atención integral en las personas diagnosticadas con tuberc...ulosis y virus de Inmunodeficiencia Humana (VIH), que incluyen acciones de prevención, diagnóstico, tratamiento y seguimiento.more
Trachoma is one of the 17 WHO-defined Neglected Tropical Diseases
(NTDs) that affect over 1 billion of the world’s poorest and most
marginalized people. It is caused by the bacterium chlamydia trachomatis.
This publication describes the first WHO public-benefit Target Product Profiles (TPPs) for snakebite antivenoms. It focuses on antivenoms for treatment of snakebite envenoming in sub-Saharan Africa. Four TPPs are described in the document:
Broad spectrum Pan-African polyvalent antivenoms: products ...that are intended for widespread utility throughout sub-Saharan Africa for treatment of envenoming irrespective of the species of snake causing a bite. Monovalent antivenoms for specific use cases: for products for a single species (or genus) of snake (e.g., boomslangs or carpet viper antivenoms).
Syndromic Pan-African polyvalent antivenoms for neurotoxic envenoming: products that are intended for treatment of envenoming by species whose venoms are neurotoxic. Syndromic Pan-African polyvalent antivenoms for non-neurotoxic envenoming: products for snakebite envenoming where the effects are largely haemorrhagic, necrotic or procoagulant.more